+

WO2001009325A3 - Mutations du gene p53 humain, et systeme genetique de levures utilise pour l'identification fonctionnelle des mutations du gene p53 humain - Google Patents

Mutations du gene p53 humain, et systeme genetique de levures utilise pour l'identification fonctionnelle des mutations du gene p53 humain Download PDF

Info

Publication number
WO2001009325A3
WO2001009325A3 PCT/US2000/020538 US0020538W WO0109325A3 WO 2001009325 A3 WO2001009325 A3 WO 2001009325A3 US 0020538 W US0020538 W US 0020538W WO 0109325 A3 WO0109325 A3 WO 0109325A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutations
human
supertransactivating
toxic
indentification
Prior art date
Application number
PCT/US2000/020538
Other languages
English (en)
Other versions
WO2001009325A9 (fr
WO2001009325A2 (fr
Inventor
Michael A Resnick
Alberto Inga
Original Assignee
Us Health
Michael A Resnick
Alberto Inga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Michael A Resnick, Alberto Inga filed Critical Us Health
Priority to AU62395/00A priority Critical patent/AU784293B2/en
Priority to JP2001514117A priority patent/JP2003506041A/ja
Priority to EP00948979A priority patent/EP1204745A2/fr
Priority to CA002380631A priority patent/CA2380631A1/fr
Priority to US10/048,502 priority patent/US7256260B1/en
Publication of WO2001009325A2 publication Critical patent/WO2001009325A2/fr
Publication of WO2001009325A3 publication Critical patent/WO2001009325A3/fr
Publication of WO2001009325A9 publication Critical patent/WO2001009325A9/fr
Priority to AU2006202361A priority patent/AU2006202361A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des polypeptides isolés du gène p53 humain renfermant des mutations. Ces mutations peuvent être des mutations toxiques, des mutations supertransactivatrices ou des mutations de suppression du phénotype toxique. L'invention concerne également des méthodes d'identification de ces mutations toxiques, supertransactivatrices, faiblement transactivatrices et de suppression du phénotype toxique, ainsi que des méthodes d'identification de composés imitant les mutations toxiques, supertransactivatrices et de suppression du phénotype toxique du gène p53 humain. L'invention concerne enfin des méthodes permettant d'induire une toxicité dans une cellule par administration d'un polypeptide comprenant une mutation supertransactivatrice ou toxique.
PCT/US2000/020538 1999-07-30 2000-07-28 Mutations du gene p53 humain, et systeme genetique de levures utilise pour l'identification fonctionnelle des mutations du gene p53 humain WO2001009325A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU62395/00A AU784293B2 (en) 1999-07-30 2000-07-28 Human P53 mutations and a genetic system in yeast for functional indentification of human P53 mutations
JP2001514117A JP2003506041A (ja) 1999-07-30 2000-07-28 ヒトｐ５３変異およびヒトｐ５３変異の機能的同定のための酵母遺伝子系
EP00948979A EP1204745A2 (fr) 1999-07-30 2000-07-28 Mutations du gene p53 humain, et systeme genetique de levures utilise pour l'identification fonctionnelle des mutations du gene p53 humain
CA002380631A CA2380631A1 (fr) 1999-07-30 2000-07-28 Mutations du gene p53 humain, et systeme genetique de levures utilise pour l'identification fonctionnelle des mutations du gene p53 humain
US10/048,502 US7256260B1 (en) 1999-07-30 2000-07-28 Human p53 mutations and a genetic system in yeast for functional identification of human p53 mutations
AU2006202361A AU2006202361A1 (en) 1999-07-30 2006-06-02 Human P53 mutations and a genetic system in yeast for functional identification of human P53 mutations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14663499P 1999-07-30 1999-07-30
US60/146,634 1999-07-30

Publications (3)

Publication Number Publication Date
WO2001009325A2 WO2001009325A2 (fr) 2001-02-08
WO2001009325A3 true WO2001009325A3 (fr) 2001-08-30
WO2001009325A9 WO2001009325A9 (fr) 2002-08-08

Family

ID=22518261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020538 WO2001009325A2 (fr) 1999-07-30 2000-07-28 Mutations du gene p53 humain, et systeme genetique de levures utilise pour l'identification fonctionnelle des mutations du gene p53 humain

Country Status (5)

Country Link
EP (1) EP1204745A2 (fr)
JP (1) JP2003506041A (fr)
AU (1) AU784293B2 (fr)
CA (1) CA2380631A1 (fr)
WO (1) WO2001009325A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256260B1 (en) 1999-07-30 2007-08-14 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, Nih Human p53 mutations and a genetic system in yeast for functional identification of human p53 mutations
ES2406077T3 (es) * 2007-05-31 2013-06-05 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Vacuna de péptido p53
CN110257467A (zh) * 2019-07-22 2019-09-20 福州市皮肤病防治院 一种检测肿瘤抑制因子p53显性抑制突变的试剂盒及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016989A1 (fr) * 1994-11-28 1996-06-06 The Wistar Institute Of Anatomy And Biology PROTEINES p53 A DOMAINES DE TETRAMERISATION MODIFIES
WO1997041136A1 (fr) * 1996-05-01 1997-11-06 The Johns Hopkins University Mutation de suppresseurs des mutations cancereuses p53 courantes
WO2000022115A2 (fr) * 1998-10-13 2000-04-20 Board Of Regents, The University Of Texas System Dosages permettant d'identifier des alterations fonctionnelles dans le gene suppresseur de tumeur p53
WO2000068384A2 (fr) * 1999-05-12 2000-11-16 Xencor, Inc. Nouveaux acides nucleiques et proteines ayant une activite p53 et comportant des domaines de tetramerisation modifies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506001A (ja) * 1992-10-01 1996-07-02 ザ ゼネラル ホスピタル コーポレーション 腫瘍サプレッサー遺伝子の機能検査
EP0796277B1 (fr) * 1994-11-28 2004-03-24 Thomas Jefferson University Vaccin tumoral peptidique base sur la jonction de fusion du recepteur egf type iii mute

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016989A1 (fr) * 1994-11-28 1996-06-06 The Wistar Institute Of Anatomy And Biology PROTEINES p53 A DOMAINES DE TETRAMERISATION MODIFIES
WO1997041136A1 (fr) * 1996-05-01 1997-11-06 The Johns Hopkins University Mutation de suppresseurs des mutations cancereuses p53 courantes
WO2000022115A2 (fr) * 1998-10-13 2000-04-20 Board Of Regents, The University Of Texas System Dosages permettant d'identifier des alterations fonctionnelles dans le gene suppresseur de tumeur p53
WO2000068384A2 (fr) * 1999-05-12 2000-11-16 Xencor, Inc. Nouveaux acides nucleiques et proteines ayant une activite p53 et comportant des domaines de tetramerisation modifies

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FLAMAN J -M ET AL: "A simple p53 functional assay for screening cell lines, blood, and tumors.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 9, 1995, 1995, pages 3963 - 3967, XP002153428, ISSN: 0027-8424 *
FREEMAN J ET AL: "Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 13, no. 22, 1994, pages 5393 - 5400, XP002153425, ISSN: 0261-4189 *
GAGNEBIN J ET AL: "Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.", ONCOGENE, vol. 16, no. 5, 5 February 1998 (1998-02-05), pages 685 - 690, XP000961074, ISSN: 0950-9232 *
INGA ALBERTO ET AL: "N-(2-chloroethyl)-N-nitrosourea tethered to lexitropsin induces minor groove lesions at the p53 cDNA that are more cytotoxic than mutagenic.", CANCER RESEARCH, vol. 59, no. 3, 1 February 1999 (1999-02-01), pages 689 - 695, XP002153427, ISSN: 0008-5472 *
KELLY JACK D ET AL: "Relationship between DNA methylation and mutational patterns induced by a sequence selective minor groove methylating agent.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 26, 25 June 1999 (1999-06-25), pages 18327 - 18334, XP002153426, ISSN: 0021-9258 *
MATSUMURA I ET AL: "IN VITRO EVOLUTION OF THERMOSTABLE P53 VARIANTS", PROTEIN SCIENCE,GB,CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, vol. 8, no. 4, April 1999 (1999-04-01), pages 731 - 740, XP000891282, ISSN: 0961-8368 *
SALLER ELISABETH ET AL: "Increased apoptosis induction by 121F mutant p53.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 18, no. 16, 16 August 1999 (1999-08-16), pages 4424 - 4437, XP002160228, ISSN: 0261-4189 *
SOUSSI THIERRY ET AL: "Structural aspects of the p53 protein in relation to gene evolution: A second look.", JOURNAL OF MOLECULAR BIOLOGY, vol. 260, no. 5, 1996, pages 623 - 637, XP002153429, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
CA2380631A1 (fr) 2001-02-08
WO2001009325A9 (fr) 2002-08-08
AU6239500A (en) 2001-02-19
AU784293B2 (en) 2006-03-02
JP2003506041A (ja) 2003-02-18
EP1204745A2 (fr) 2002-05-15
WO2001009325A2 (fr) 2001-02-08

Similar Documents

Publication Publication Date Title
WO2001038547A3 (fr) Polypeptides comprenant des multimeres de signaux de localisation nucleaire ou de domaines de transduction de proteine et utilisations de ces derniers pour transferer des molecules dans des cellules
WO2000060066A8 (fr) Complexes proteine-proteine de s. cerevisiae et leurs methodes d'utilisation
IL130190A0 (en) Methods and compositions for polypeptide engineering
ZA975156B (en) Electrode material for rechargeable batteries and process for the preparation thereof.
CA2075060A1 (fr) Essences pour vehicules et leur utilisation dans des preparations medicales
AU6037198A (en) System for delivering and simultaneously displaying primary and secondary information, and for displaying only the secondary information during interstitial space
AU9403698A (en) Sputter-deposited fuel cell membranes and electrodes
WO1999045098A3 (fr) Apport de proteines a des cellules eucaryotes au moyen de la yersinia recombinee
AU6933496A (en) Antagonists of the oncogenic activity of the MDM2 protein and their use in the treatment of cancers
AU2240197A (en) Use of toxin peptides and/or affinity handles for delivery compounds into cells
WO1999025843A3 (fr) Kinase humaine de controle, hcds1, compositions et procedes
AU3365499A (en) Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof
AU3387500A (en) Cells resistant to toxic genes and uses thereof
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
AU5789499A (en) (neisseria meningitidis) polypeptide, nucleic acid sequence and uses thereof
WO2001049721A3 (fr) Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations
WO1997045746A3 (fr) Proteines de liaison a la proteine de prion
AU6322598A (en) Case for combustible materials and methods for making and using the same
AU6458400A (en) Nucleic acid, polypeptides, assays, therapeutic methods and means
EP0808323A4 (fr) MUTANTS DES GENES Rb ET p53 ET LEUR EMPLOI
AU7180294A (en) Reaction cell for protein sequencer and the like
WO2001009325A3 (fr) Mutations du gene p53 humain, et systeme genetique de levures utilise pour l'identification fonctionnelle des mutations du gene p53 humain
AU3383095A (en) Cell adhesion peptides for use in modifying mutual adhesion among eukaryotic cells
AU9269898A (en) Artificial viruses derived from papillomavirus, and their uses, in particular gene therapy
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2380631

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 62395/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000948979

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000948979

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10048502

Country of ref document: US

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 98-102, 105 AND 106, DESCRIPTION, REPLACED BY NEW PAGES 98-102, 105 AND 106; PAGES 1/18-18/18, DRAWINGS, REPLACED BY NEW PAGES 1/18-18/18; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载